SCHEMBL5830740

SCHEMBL5830740

O=C(Cc1nsc(NS(=O)(=O)c2ccc(-c3ccncc3)cc2)n1)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.46
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TSHR P16473 1/20 0.38
PIK3R1 P27986 4/20 0.38
PIK3CA P42336 4/20 0.38
MTOR P42345 4/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831705 0.91 MAPT (0.52) HSD11B1ALDH1A1KMT2AMAPK1MAPT
SCHEMBL5830800 0.90 HSD11B1 (0.51) HSD11B1ALDH1A1KMT2AMAPK1MAPT
SCHEMBL5831227 0.90 HSD11B1 (0.44) HSD11B1ALDH1A1KMT2AMAPK1MAPT
SCHEMBL5831527 0.88 ALDH1A1 (0.54) HSD11B1ALDH1A1KMT2AMAPK1MAPT
SCHEMBL5830925 0.87 HSD11B1 (0.44) HSD11B1ALDH1A1KMT2AMAPK1MAPT
SCHEMBL5830646 0.87 HSD11B1 (0.50) HSD11B1ALDH1A1KMT2AMAPK1LMNA
SCHEMBL5831503 0.85 HPGD (0.44) HSD11B1ALDH1A1KMT2AMAPTLMNA
SCHEMBL5831281 0.85 KMT2A (0.45) HSD11B1ALDH1A1KMT2AMAPTLMNA
SCHEMBL5831402 0.85 KMT2A (0.47) HSD11B1ALDH1A1KMT2AMAPK1LMNA
SCHEMBL5830837 0.85 ALDH1A1 (0.43) HSD11B1ALDH1A1KMT2AMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885ALDH1A1 63/4885KMT2A 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.